 | Up a level |
Janssen, J J W M; Löwenberg, B; Manz, M; Biemond, B J; Westerweel, P E; Klein, S K; Fehr, M; Sinnige, H A M; Efthymiou, A; Legdeur, M C J C; Pabst, T; Gregor, M; van der Poel, M W M; Deeren, D; Tick, L W; Jongen-Lavrencic, M; van Obbergh, F; Boersma, R S; de Weerdt, O; Chalandon, Y; ... (2022). Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. Leukemia, 36(9), pp. 2189-2195. Nature Publishing Group 10.1038/s41375-022-01657-3
Uppugunduri, C R S; Huezo-Diaz Curtis, P; Nava, T; Rezgui, M A; Mlakar, V; Mlakar, S Jurkovic; Waespe, N; Théoret, Y; Gumy-Pause, F; Bernard, F; Chalandon, Y; Boelens, J J; Bredius, R G M; Dalle, J H; Nath, C; Corbacioglu, S; Peters, C; Bader, P; Shaw, P; Bittencourt, H; ... (2022). Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation. Pharmacogenomics journal, 22(1), pp. 9-18. Nature Publishing Group 10.1038/s41397-021-00251-7
